Molecular diagnosis of mast cell disorders - A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology

被引:55
作者
Akin, Cem [1 ]
机构
[1] Univ Michigan, Dept Internal Med, Div Allergy & Immunol, Ann Arbor, MI 48109 USA
关键词
D O I
10.2353/jmoldx.2006.060022
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Mastocytosis is a disease characterized by pathological mast cell accumulation and activation in tissues. Most patients with mastocytosis exhibit the D816V point mutation in the tyrosine kinase domain of the transmembrane receptor protein Kit, leading to its constitutive activation in bone marrow or lesional skin tissue. Detection of a codon 816 c-kit mutation is included as a minor diagnostic criterion in the World Health Organization's diagnostic criteria for systemic, mastocytosis. Determining mutational status of the c-kit gene also has pharmacogenomic implications in patients considered for investigational mast cell cytoreductive therapies. This article reviews diagnostic and therapeutic implications of c-kit mutations as well as other less common molecular abnormalities observed in mast cell disease.
引用
收藏
页码:412 / 419
页数:8
相关论文
共 57 条
[21]   Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia [J].
Goemans, BF ;
Zwaan, CM ;
Miller, M ;
Zimmermann, M ;
Harlow, A ;
Meshinchi, S ;
Loonen, AH ;
Hählen, K ;
Reinhardt, D ;
Creutzig, U ;
Kaspers, GJL ;
Heinrich, MC .
LEUKEMIA, 2005, 19 (09) :1536-1542
[22]   Molecular classification and pathogenesis of eosinophilic disorders: 2005 update [J].
Gotlib, J .
ACTA HAEMATOLOGICA, 2005, 114 (01) :7-25
[23]   Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation [J].
Gotlib, J ;
Berubé, C ;
Growney, JD ;
Chen, CC ;
George, TI ;
Williams, C ;
Kajiguchi, T ;
Ruan, J ;
Lilleberg, SL ;
Durocher, JA ;
Lichy, JH ;
Wang, YF ;
Cohen, PS ;
Arber, DA ;
Heinrich, MC ;
Neckers, L ;
Galli, SJ ;
Gilliland, DG ;
Coutré, SE .
BLOOD, 2005, 106 (08) :2865-2870
[24]  
Hannaford R, 2001, Australas J Dermatol, V42, P15, DOI 10.1046/j.1440-0960.2001.00466.x
[25]   Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor [J].
Heinrich, MC ;
Griffith, DJ ;
Druker, BJ ;
Wait, CL ;
Ott, KA ;
Zigler, AJ .
BLOOD, 2000, 96 (03) :925-932
[26]   Diagnostic value of immunostaining for tryptase in patients with mastocytosis [J].
Horny, HP ;
Sillaber, C ;
Menke, D ;
Kaiserling, E ;
Wehrmann, M ;
Stehberger, B ;
Chott, A ;
Lechner, K ;
Lennert, K ;
Valent, P .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1998, 22 (09) :1132-1140
[27]  
Jurgens DJ, 2004, HAEMATOLOGICA, V89, P1394
[28]   PEDIATRIC MASTOCYTOSIS [J].
KETTELHUT, BV ;
METCALFE, DD .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1991, 96 (03) :S15-S18
[29]   Cutaneous mastocytosis in children:: a clinical analysis of 71 cases [J].
Kiszewski, AE ;
Durán-Mckinster, C ;
Orozco-Covzrrubias, L ;
Gutiérrez-Castrellón, P ;
Ruiz-Maldonado, R .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2004, 18 (03) :285-290
[30]   Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome [J].
Klion, AD ;
Robyn, J ;
Akin, C ;
Noel, P ;
Brown, M ;
Law, M ;
Metcalfe, DD ;
Dunbar, C ;
Nutman, TB .
BLOOD, 2004, 103 (02) :473-478